%0 Journal Article
%A Mena-Vázquez, Natalia
%A Rojas-Gimenez, Marta
%A Romero-Barco, Carmen María
%A Manrique-Arija, Sara
%A Hidalgo Conde, Ana
%A Arnedo Díez de Los Ríos, Rocío
%A Cabrera César, Eva
%A Ortega-Castro, Rafaela
%A Espildora, Francisco
%A Aguilar-Hurtado, María Carmen
%A Añón-Oñate, Isabel
%A Pérez-Albaladejo, Lorena
%A Abarca-Costalago, Manuel
%A Ureña-Garnica, Inmaculada
%A Velloso-Feijoo, Maria Luisa
%A Redondo-Rodriguez, Rocio
%A Fernández-Nebro, Antonio
%T Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study.
%D 2021
%@ 2075-4418
%U https://hdl.handle.net/10668/25698
%X To describe the characteristics and progression of interstitial lung disease in patients with associated systemic autoimmune disease (ILD-SAI) and to identify factors associated with progression and mortality. We performed a multicenter, retrospective, observational study of patients with ILD-SAI followed between 2015 and 2020. We collected clinical data and performed pulmonary function testing and high-resolution computed tomography at diagnosis and at the final visit. The main outcome measure at the end of follow-up was forced vital capacity (FVC) >10% or diffusing capacity of the lungs for carbon monoxide >15% and radiological progression or death. Cox regression analysis was performed to identify factors associated with worsening of ILD. We included 204 patients with ILD-SAI: 123 (60.3%) had rheumatoid arthritis (RA), 58 had (28.4%) systemic sclerosis, and 23 (11.3%) had inflammatory myopathy. After a median (IQR) period of 56 (29.8-93.3) months, lung disease had stabilized in 98 patients (48%), improved in 33 (16.1%), and worsened in 44 (21.5%). A total of 29 patients (14.2%) died. Progression and hospitalization were more frequent in patients with RA (p = 0.010). The multivariate analysis showed the independent predictors for worsening of ILD-SAI to be RA (HR, 1.9 [95% CI, 1.3-2.7]), usual interstitial pneumonia pattern (HR, 1.7 [95% CI, 1.0-2.9]), FVC (%) (HR, 2.3 [95% CI, 1.4-3.9]), and smoking (HR, 2.7 [95%CI, 1.6-4.7]). Disease stabilizes or improves after a median of 5 years in more than half of patients with ILD-SAI, although more than one-third die. Data on subgroups and risk factors could help us to predict poorer outcomes.
%K interstitial lung disease
%K prognosis
%K rheumatoid arthritis
%K systemic autoimmune disease
%~